BiotechTube

YM872 (zonampanel)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident

Trial Timeline

Dec 1, 2000 → Jan 1, 2003

NCT ID
NCT00044070

About YM872 (zonampanel)

YM872 (zonampanel) is a phase 2 stage product being developed by Astellas Pharma for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT00044070. Target conditions include Cerebrovascular Accident.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00044070Phase 2Completed

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors
ProductCompanyStageHype Score
donepezil hclEisaiPhase 3
77
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
85
ONO-2506Ono PharmaceuticalPhase 2/3
65
AbciximabEli LillyPhase 3
77
atomoxetine + StimulantsEli LillyPre-clinical
23
ticagrelor + ASA + Placebo+ASAAstraZenecaApproved
85
ValsartanNovartisPre-clinical
23
AtorvastatinPfizerApproved
84
RivaroxabanBayerPre-clinical
20
Darolutamide (BAY1841788) + EnzalutamideBayerPhase 1
30
Botulinum toxin type A + PlaceboIpsenApproved
82
Atorvastatin 20mgBrain BiotechApproved
77
Autologous bone marrow mononuclear cell transplantationBrain BiotechPhase 1
25
Roflumilast Oral TabletBrain BiotechPhase 2
44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85